Evotec International GMBH
Hamburg, HH
Company facts
- Self-certified in SAM.gov
- Entity structure
- International Organization
- SAM.gov registration date
- Physical address
- Essener Bogen 7, 22419 Hamburg, Germany
- Website
- evotec.com
- Founded
- 1993
- Employees
- 1K-5K
- Estimated annual revenue
- $1B-$10B
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Proof of concept for a molecular glue approach to treat ALS | Defense Health Agency | $654,391 | |
| Monoclonal antibody against chikungunya virus for therapeutic and prophylactic indications | Interior Business Center (DO) | $661,847 |
Similar vendors
About the company
Evotec International GMBH is a leading drug discovery and development company that provides standalone drug discovery services and integrated drug discovery collaborations. As an international organization registered to receive federal awards from the U.S. government, Evotec specializes in biomedical research and drug development projects, particularly in the areas of antibacterial drugs, monoclonal antibody therapeutics, and treatments for neurodegenerative diseases. The company's expertise in these fields has made it a valuable partner for various U.S. government agencies seeking innovative solutions to pressing health challenges. Evotec's capabilities span from early-stage research to preclinical and clinical development, offering a comprehensive approach to drug discovery and development.
Through federal contract awards, Evotec International GMBH has primarily served as a subcontractor on projects aimed at developing novel antibacterial drugs. A notable example is their involvement in a CARB-X funded project, awarded through the Trustees of Boston University, to develop an IV-administered broad-spectrum antibacterial drug candidate. This project focuses on addressing severe hospital infections caused by multi-drug resistant pathogens. Evotec's work involves optimizing a new class of compounds that simultaneously target two essential bacterial enzymes with a novel mode of action. The goal is to advance a promising compound into clinical studies, potentially delivering a groundbreaking broad-spectrum antibacterial drug to the clinic. This project showcases Evotec's capability to contribute to cutting-edge research in combating antibiotic resistance, a critical concern in public health.
Evotec International GMBH has also received federal grant awards for various biomedical research projects. In a recent award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420), Evotec secured a $654,391 project grant to conduct a proof of concept study for a molecular glue approach to treat Amyotrophic Lateral Sclerosis (ALS). This project, scheduled from 2024 to 2026, demonstrates Evotec's involvement in researching innovative treatments for neurodegenerative diseases. Additionally, Evotec was awarded a $661,847 cooperative agreement from the Department of the Interior Departmental Offices Interior Business Center for a project involving a monoclonal antibody against Chikungunya virus for therapeutic and prophylactic indications. This project, which ran from 2022 to 2023, highlights Evotec's capabilities in developing treatments for infectious diseases. These grant awards underscore Evotec's diverse research portfolio and its ability to secure funding from various U.S. government agencies for projects spanning different areas of medical research and drug development.
Quick answers
Is Evotec International GMBH registered in SAM.gov?
Yes. Evotec International GMBH's SAM.gov registration is active through May 27, 2027.
What is Evotec International GMBH's CAGE code?
Evotec International GMBH's CAGE code is CL152, and its Unique Entity ID (UEI) is LF5NR8KMJLG6.
What is Evotec International GMBH's most recent federal award?
Evotec International GMBH's most recent federal grant award is Proof of concept for a molecular glue approach to treat ALS (HT94252410148), from Defense Health Agency, on April 1, 2024.
On GovTribe
See Evotec International GMBH's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors